Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 129.81 USD 5.85% Market Closed
Market Cap: 7.4B USD
Have any thoughts about
Ascendis Pharma A/S?
Write Note

Ascendis Pharma A/S
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ascendis Pharma A/S
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Ascendis Pharma A/S
NASDAQ:ASND
Net Issuance of Common Stock
€29.8m
CAGR 3-Years
-64%
CAGR 5-Years
-44%
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Net Issuance of Common Stock
-kr3.5B
CAGR 3-Years
-125%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Net Issuance of Common Stock
kr8.2B
CAGR 3-Years
123%
CAGR 5-Years
65%
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Net Issuance of Common Stock
-kr660k
CAGR 3-Years
N/A
CAGR 5-Years
38%
CAGR 10-Years
N/A
F
Fluoguide AS
STO:FLUO
Net Issuance of Common Stock
kr17.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Net Issuance of Common Stock
kr81.4m
CAGR 3-Years
-10%
CAGR 5-Years
1%
CAGR 10-Years
N/A
No Stocks Found

Ascendis Pharma A/S
Glance View

Market Cap
7.6B USD
Industry
Biotechnology

Ascendis Pharma A/S is a biopharmaceutical company that is dedicated to transforming the lives of patients through innovative therapies, particularly in the areas of endocrine diseases, oncology, and rare diseases. Founded in 2006 and based in Copenhagen, Denmark, Ascendis has developed a unique platform called TransCon technology, which enables the creation of new medicines that enhance the therapeutic potential of existing drugs. This innovative approach is designed to improve dosing regimens and reduce side effects, positioning Ascendis as a game-changer in the pharmaceutical landscape. With a robust pipeline, including its lead product candidate, TransCon Growth Hormone, currently in late-stage development for growth hormone deficiency, the company is strategically positioned to capture significant market potential. For investors, Ascendis Pharma represents an enticing opportunity within the biopharmaceutical sector, particularly as it navigates pivotal clinical trials and potential regulatory approvals. The company boasts a strong financial foundation, having secured substantial funding from partnerships and public offerings to support its clinical programs. With a growing emphasis on long-term value creation derived from its innovative approach to drug development, Ascendis aims to become a key player in addressing unmet medical needs. As it advances its pipeline and explores partnerships with larger pharmaceutical companies, beckoning the prospects of lucrative collaborations, investors have a chance to become involved in the journey of a company poised at the intersection of science and patient care.

ASND Intrinsic Value
118.13 USD
Overvaluation 9%
Intrinsic Value
Price

See Also

What is Ascendis Pharma A/S's Net Issuance of Common Stock?
Net Issuance of Common Stock
29.8m EUR

Based on the financial report for Jun 30, 2024, Ascendis Pharma A/S's Net Issuance of Common Stock amounts to 29.8m EUR.

What is Ascendis Pharma A/S's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-44%

Over the last year, the Net Issuance of Common Stock growth was 356%. The average annual Net Issuance of Common Stock growth rates for Ascendis Pharma A/S have been -64% over the past three years , -44% over the past five years .

Back to Top